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1Incidental finding of sickle cell trait from an everyday diabetes 
test  should the family practitioner report? retest? refer?
In Brief
The HbA1c test is increasingly widely used as a diagnostic and screening test for diabetes mellitus 
type 2 (T2DM) but the presence of haemoglobin variants, such as sickle haemoglobin, can cause some 
interference with results in some analytical systems. These interferences are sometimes reported 
onoccasionally reported by laboratoriesy results, leading unprepared patients to suspect they are may 
be sickle cell carriers and seek confirmation through a sickle cell test. 
Incidental findings of Hb variants, and the reporting thereof, present multiple ethical challenges to 
laboratories, medical practitioners, patients and their family members, but and there appears to be no 
international or national guidelines on how to deal with the reporting of these findings. 
This paper explores issues such as whether informed consent is or isnt necessary,; how the results 
should be communicated,; how the patient may be affected by knowing their carrier status,; the timing 
of communications,; complications caused by partial results, and being a healthy carrier at the same 
time as potentially experiencing symptoms.
Introduction
The HbA1c test is increasingly widely used as a diagnostic and screening test for T2DMdiabetes 
mellitus type 2.  With an estimated 8.8% of adults globally having diabetes mellitus, effective 
screening, diagnosis and monitoring is of major global importance1. The biomarker of HbA1c refers to 
glycated haemoglobin A (A1c) molecules and has gained prominence in the diagnosis of T2DM due to 
certain advantages over plasma glucose testing regimenssome advantages over plasma glucose tests2. 
It is well established that that some haemoglobin (Hb) variants, of which there are hundreds, including 
the clinically relevant HbS, HbE, HbC, and HbD3, 4 may interfere with the validity of the HbA1c 
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2results, meaning these testing strategies and tools s should ideally identify variants where they are 
presentnecessary. 
Incidental findings of Hb variants present several ethical challenges for laboratories, medical 
practitioners, patients and their familyies members. These challenges have, to date, received little 
attention. This paper discusses some of the advantages of detecting sickle cell trait, identified by the 
routinetriggeredthrough the everyday  HbA1c test, but also several ethical dilemmas. 
A multidisciplinary team and a patient that was diagnosed as a sickle cell carrier through the HbA1c 
test worked together to explore these ethical challenges to produce this paper. It and we it is hoped 
this paper will initiate instigate discussiondiscourse around the issues presented and ultimately lead to 
the development of appropriate international guidelines for practice.
What does the sickle cell allele have to do with the HbA1c test for 
type 2 diabetes type 2?
Sickle haemoglobin (HbS) is one of the most common haemoglobin variants. Worldwide an estimated 
300 million people have sickle cell trait (SCT) and ~4.4 million people have sickle cell disease 
(SCD), SCD being the overall name for a group of disorders 5,6. Sickle cell disease can be life 
threatening, or increase risk of complications such as stroke, organ failure and acute chest syndrome7. 
Although SCT is usually clinically silent, there are rare complications sequelae e.g.such as haematuria 
and splenic infarction8,9 and potentially a higher risk of T2DMdiabetes type 2 related complications  
such as retinopathy, nephropathy, and hypertension10. The sickle cell allele is present worldwide and w. 
Whilst there is perhaps more awareness and research of SCT in African American populations, a 
higher incidence of SCT is also found in Middle Eastern, Mediterranean, Indian and Latin American 
populations611.
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3Whereas there is a handful of are few methodological variations inof the glucose tolerance test assays 
used to diagnose diabetes mellitus, the different methods and systems available and vast number of 
systems usedavailable for the HbA1C test, in comparison, is a challenge in terms of understanding 
when Hbhaemoglobin variants might interefere with the system in use.  According to the National 
Glycohaemoglobin Standardisation Programme (NGSP) in the U.S.A. there are 6 six method types 
available for measuring HbA1c; which are iImmunoassay, borate affinity, enzymatic, ion-exchange 
high performance liquid chromatography (HPLC) and capillary electrophoresis and or borate affinity, 
HPLC. Currently, there are >There are over 200 analytical systems developed by approximately 70 
companies, and >150+ of themse systems  are available in the USA. There is also a range of 
susceptibility to interference by, and ability to recognise, Hb variants11,12,13,14,15 . Some of these 
systems are in laboratories, while and some are used as in point of care situationsfacilities156t   Table 1 
below summarises the NGSPs data on HbA1c testing systems:
Table 1. Numbers of methods, systems for HbA1c tests and their interference with variants 
Whilst the number of systems with a reported interference by HbS is relatively low, these could be in 
the more widelycommonly used systems, and the figures demonstrate there is relatively little research 
to confirm whether or not there is interference of HbS with the majority of themse systems. According 
to NGSP, only 16% of all systems have been evaluated using robust methods, 57% of these showed 
an interference with at least one Hbhaemoglobin type and 19% with HbS. Interference was found with 
more than one method type but the same method came out with no interference with other systems167.  
Furthermore, tThese systems may also require expert interpretation of results. For example, the 
electrophoretic principle is based on the separation of constituent particles e.g. haemoglobin in a 
mobile/liquid phase,  and  interaction and subsequent retention by on a solid phase according to in the 
system, according to their physicochemical properties. Elution from the solid phase, and subsequent 
detection, results in a chromatogram where the area of the peak corresponds with concentration of the 
analytes compounds detected. EThe electrophoresis is essentially separating haemoglobins with 
different properties, such as glycated Hb or variants, which result in different peaks in a 
Page 3 of 23
For Peer Review
Clinical Diabetes MS -- Not for Distribution
4chromatogram. An expert eyeExpertise is required to properly adequately interpret chromatographs, 
as some variants may be hidden in the HbA peak, potentially sometimes changing its height, width 
and/or shape. Therefore it is important for the physician to know if a variant that interferes with the 
validity of the HbA1c test is present, so that an alternative method or analytical technique may be used. 
to use an alternative method if screening for diabetes type 2 where there is no variant interference 
because the results may not be comparable with internationally established reference values based on 
HbAA studies. 
Example of an incidental finding of sickle cell trait from a HbA1c 
test
Against this background of a huge diversity of methods and systems, what might the patient 
experience be of the result of this test for someone who had no prior knowledge of having sickle cell 
trait (HbAS)? The patient involved in the case described here queiried the result of haemoglobin 
variant detected with their family physician, who said they were probably a carreier for sickle cell 
disease and only on the request of the patient,  referred him for a sickle cell test to confierm this. on 
request of the patient. On confirmation of SCT status, no support of genetic counselling was offered. 
to the patient. 
Below is an example of athe chromatogram held in the laboratory files for the above patient, showing 
a HbS variant detected using the Tosoh (HPLC) system when a HbA1c test was requested by a the 
primary care practitioner:
Fig 1 Example of chromatogram for a patient with HbAS detected through a HbA1c test, in laboratory 
files only :
Fig 2 below shows how the above result was first communicated to the referring practitioner and 
ultimately the patient who had requested a printout from a series of blood tests. 
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5Fig 2 Extract of lab report showing wording of the HbA1c result sent to the practitioner and then 
passed onto the patient
The information provided in Fig. 2 on the haemoglobin variant is fairly limited in its usefulness 
because it does not provide information on what the variant might be, whether there is one copy of the 
variant allele (heterozygous; e.g. HbAS) or two (homozygous; e.g. HbSS) or a combination of 
different haemoglobin variants. The information in Figure 1 may be more useful in this respect, but 
this is not generally released in laboratory reports due to the expert interpretation often required. 
Therefore, what primary care practitioners may infer from this may be highly variable, or nothing at 
all, particularly as the result has been classified as Normal. They may choose to, or not to, discuss 
further tests to establish which Hb variant the patient has, or the patient may come to their own 
conclusions with or without the aid of an online search revealing research, policies and SCT linked 
death prevention campaigns17,18. 
There are currently no international guidelines for the reporting of incidental finding of possible 
Hbhaemoglobin variants through HbA1c tests. Although the World Health OrganisationW.H.O. 
guidelines on the use of the HbA1c test refer to interference from haemoglobin variants, they do not 
advise on if, when or how to inform a primary care practitioner or patient of a variant that has been 
detected1919.  
Almost a year after the above test was produced, the laboratoryhe trust involved refined its reporting 
to practitioners with the following note, where there are heterozygous variants only e.gi.e. HbAS. It is 
highly unlikely that reporting is uniform across hospital laboratoriestrusts in the UK even when using 
the same systems:
Fig 3 Updated wording of the HbA1c result sent to the practitioners a year after the above result
Advantages of detecting a sickle cell trait through the HbA1c test
Page 5 of 23
For Peer Review
Clinical Diabetes MS -- Not for Distribution
6There could be some advantages for detecting haemoglobin variants through diabetes type 2T2DM  
screening. The first advantage is that it is important to note for such a patient that a diagnosis of 
T2DMype 2 diabetes mellitus must not be made using a HbA1c testing system affected by variants. 
This is important for affectedsuch individuals but also at a population level in regions such as sub-
Saharan Africa where between 10% and 40% of people have SCT2020, but many may not know their 
status as screening programmes are rare.  The HbA1c test may still, however, have some use for 
monitoring a patient who has already been diagnosed with diabetes T2DM because the comparison is 
then between the patients own results over time rather than comparing with others. 
The HbA1c test is generally not suitable for rapid onset in any clinical conditionsituation where there 
isnt enough HbA with a normal that affects the  lifespan (~120 days) of erythrocytes e.g. the presence 
ofsuch as for some Hb variants, intravascular haemolysis, and in  liver disease, or where there is a 
rapid onset of diabetes but a normal HbA1c such as gestational diabetes and type 1 diabetes (T1DM). 
The case of HbAS, like that presented here,  isnt even as simple as expecting the Hb to be neatly 
divided into half 50% HbA and 50%half HbS, as people with HbAS almost always have more HbA 
than HbS. , and due to in aIn a sickle cell genetic carrier HbS levels may vary between 20 and 45%,  
so there is considerable variation even within those who are HbAS. Interpreting these results requires 
someone with expertise in haemoglobinopathies21..21   Additionally, most people have a small 
percentage of foetal haemoglobin (HbF), so a standardised value for HbA1c in HbAS types would 
probably not be possible. Additionally some point of care  HbA1c testing systems, often those used in 
pharmacies and GP family physician practices in the UK have no capacity to detect variants, so the 
absence of variant detection should not be assumed to be completely reliable. 
The second advantage is that further testing ,  can be done to confirm a carrier status such as SCT. 
Knowing their carrier status gives them affected individuals the opportunity to make informed 
reproductive choices and inform family members so they can consider getting tested for SCT. A few 
countries worldwide have neonatal screening for sickle cell, but these are not always where SCT is 
most common2220. Even where newborn screening is offered parents may not have been informed of 
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7the result, understood it or remembered it2223. In one report aAn estimated 40% of people in the USA 
with SCT did not know their status2423.  Therefore, detecting SCT through a relatively common test 
such as HbA1c could increase the diagnosis and knowledge of carrier status. It could also alert family 
members of the possibility of a child being born with SCD, especially where newborn screening is 
absent or sporadic. In sub-Saharan Africa, treatments are limited and an estimated 5080% of infants 
born with SCD in Africa die before the age of 5 years of age2524. In 2009 the UN General Assembly 
declared SCD to be a major public health concern2625 with 1 in 30 deaths of children under-5 
worldwide linked to haemoglobin disorders, most of these being SCD2726
.
Ethical challenges presented by incidental findings of sickle cell 
trait through the HbA1c test 
THowever there may be more challenges than advantages presented by incidental findings of Hb 
variants, some of which are discussed belowhere. 
The first ethical challenge is that any testing in which Hbhaemoglobin variants are incidentally 
revealed could be considered a genetic test, or a partial one. Some practitioners may not have 
anticipated this result, gained consent for this kind of genetic screening, or judged consent to be 
necessary. This may put them in a difficult position as not obtaining consent goes against many 
guidelines for consent for genetic screening2827,28, 29, 30,29,30,31   whilst leaving the health practitioner  
unsupported in the absence of any guidelines of what to do when Hb variant results appearis present 
in their patient. This problem, if following such guidelines,  is potentially an additional burden on 
health care professionals, especially where SCT is most common. Patients are likely to have no idea 
agreeing for a test for diabetes may throw up an unexpected indication they are a carrier of the sickle 
cell gene. Therefore patients, as well as practitioners, would have to be fully informed of the 
consequences of agreeing to such a test.   While we note the trait is largely silent, it does have some 
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8(rare) clinical consequences, which does create the further dilemma of having information which 
might have a clinical significance, but not passing that information on.  Additionally there is a risk of 
under diagnosis of diabetes type 2T2DM with the HbA1c test.3231.  
The second ethical challenge is that communicating results is not always straightforward. Even within 
a formalized programme such as the UKs newborn screening programme, concerns are raised about 
communicating SCT status3332  . Concerns include inconsistencies: variation in who gives the 
information and how,; how much detail to provide,; practitioner competence when devolving complex 
genetic information to non-specialist health professionals3433, and whether health records of who has 
SCT are sufficiently robust3534. Although identifying which professional or organisation is best placed 
to inform the patient of the newly discovered status is important, it is possible that appropriate access 
to services, such as genetic counselling appropriate for  may not actually be available. 
A third ethical challenge is that neither the patient nor the practitioner might be able to predict the full 
social impact of knowing their status as a sickle cell carrier. Subsequent racism and stigma may also 
be experienced in revealing sickle trait status which the patient may want to avoid3635. Whilst the 
different clinical impacts of SCT are disputed, there is a clear potential for societal discrimination 
through carrier status being known in several areas such as employment3637,insurance3738, sports3938, 
the criminal justice system4039  and marriageable status in some communities4140.   
A fourth ethical challenge is that patients need to have control over the results and their timing of their 
release to other family members. The result may perhaps create an unexpected moral dilemma for an 
individual, about whether to disclose to wider family members or not. For example, the patient in this 
case was a minor where one parent had requested a printout of a general blood screening where the 
wording haemoglobin variant detected was included in the normal HbA1c result. A quick online 
check indicated sickle cell trait to be the most likely explanation for this. Imagine a scenario then 
where the father of a child he thought was biologically his, received this result and he already knew 
neither he nor his partner had SCT. This result could have potentially immediate disastrous 
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9consequences for the couples relationship and family dynamics, even without a second test to 
confirm the variant type. It could be equally, or perhaps more, devastating for a child to suddenly 
learn that they are not biologically related.  In addition,  in the case of a minor both parents may have 
access to the results, leaving people potentially unprepared for situations such as unexpected 
paternity. This is one of the reasons why patients and their families need some degree of control over 
the revealing of carrier status, as well as confirmation of the result on a separate sample (mislabelled 
samples are common). 
A fifthnother ethical challenge is presented if a patient is not directly told they have a Hb variant, but 
are told they should not be screened for diabetes type 2 T2DM using the HbA1c test, for whatever 
reason. With partial information such as this the patient may seek online information and guess they 
have SCT and anxious that the trait can cause sudden death as reported with some online sources. 
They may even confuse SCT with SCD and erroneously conclude they have a serious long-term 
condition. Within this challenge are questions such as; is partial information worse than no 
information? Can the information be withheld? Should family members be informed? 
A sixth final ethical challenge could be in the everyday understanding of how SCT affects, or doesnt 
affect the body. It is confusing for patients when they are told it is both a diagnosis and is either 
mostly benign and/or is a healthy carrier state. In addition to numerous research articles available 
on the internet, of varying quality (based on evidence) and relevance, there are numerous online 
accounts of SCT patients reporting a range of symptoms they believe to be caused by SCT but not 
recognised by their physicians. This may leave anyone with SCT worried and unresolved in how they 
think ofinterpret their bodily symptoms, and how they interact with family members and their wider 
community4241. A call for a resolution to recognition of symptoms was made at a recent symposium 
including people with the trait:  You cant use this to discriminate against us, nor will you use it to 
deny us healthcare4342.
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Ways forward for testing centres, health care providers, policy 
makers and patients
In conclusion, despite some potential advantages for detecting haemoglobin variants through the 
HbA1c testing, there are several ethical and practical dilemmas to be navigated. There are questions 
around what the different HbA1c systems have to offer in terms of diagnosis, if patients should be told, 
and at what stage, and what counselling and support should they be offered.? As awareness and 
reporting grows around the various limitations of the HbA1c tests, healthcare services need to plan for 
the future to ensure provide  patient and practitioner resources and support. Guidelines for screening 
and reporting of Hbhaemoglobin variants detected in the process of assessing diabetic status currently 
revealed incidentally in the process of some tests for diabetes type 2 in a more controlled manner 
urgently need  developmentdrawing up, with the involvement of affected communities, to resolve 
these problems. This is not an isolated issue, there are other tests that can potentially throw up 
incidental findings of sickle cell trait, for example where sickled red blood cells were identified in 
urine and subsequent test revealed SCT4443 . This article has not covered thalassemias but there is 
synergy with the situation described here a parallel example in whichwhere a full blood count may be 
considered an is indirectly  a genetic test as it would reveal a patients status as a thalassaemia carrier. 
On a much wider scale, with the rise of genomic testing and precision medicine4544  this kind of 
predicament with incidental results will only present more ethical, legal and psychosocial problems 
and would benefit from time and energy being invested in guidance and solutions.
Should therefore the family physician, or the laboratories they work with report Hb variant results? 
Should they offer a further test to conform which variant they have? Should they refer the patient for 
genetic counselling? 
There appears to be three principle main choices available in the scenario of the HbA1c test and sickle 
cell trait. Firstly, either  : Either: (1) Ddispute the very notion of incidental genetic findings and 
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assert that any test that (indirectly) produces genetic findings must be declared to the client as an 
(indirect)  genetic test beforehand and appropriate permission (and counselling?) provided. Secondly, 
accept  Or (2): Accept the concept of incidental genetic findings, but then when sickle cell trait 
confounds the diabetes test, ask the client for permission to investigate possible SCT further with a 
confirmatory test for sickle cell traitSCT (and discuss with the client the implications of this) Or (3) 
AcceptThirdly, accept the concept of incidental genetic findings and focus only on the reliability of 
the information for assessing diabetes, effectively ignoring the sickle cell trait information except for 
its role as a confounder of the diabetes-relevant information. Option 1 is ethically the purest but 
potentially expensive, whereas  Ooption 3 seems downright unethical especially where the 
information could be of potential benefit to the patient and their family., but Option 2 does at least 
have the possible ethical benefits of affccording to the client the decision about whether or not to 
know about a sickle cell trait status (something that newborns arent asked when sickle cell trait is an 
incidental diagnosis to universal newborn screening for sickle cell disease).  Finding ways forward, 
therefore, would benefit from a dialogue of all parties managing aspects of this test and its results; 
laboratories, manufacturers, physicians and most importantly people with sickle cell trait, their 
families and communities. 
Key messages
 The HbA1c test is increasingly used as a standard test for diabetes type 2T2DM screening and 
monitoring and is done performed by a variety of analyticalrange of  methods. However, result 
validity, its validity, in some cases, can be affected in the presence of some Hb haemoglobin 
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variants e.g.(such as sickle haemoglobin (HbS) in some systems and other in conditions where 
red cell lifespan may be abless than normal, e.g. liver disease.
 Some, but not all, HbA1c test systems detect Hb variants, and further testing may be required to 
confirm presence of and type of Hbhaemoglobin variants
 There are currently no international, U.S., or U.K. or national level guidelines on how and when 
incidental findings should be reported to the referring practitioner or patient
 Potential advantages of detecting HbS could be to avoid HbA1c tests in future for diabetes type 
2T2DM screening and diagnosis, but the test may still be useful for monitoring HbA1c changes 
over time within individuals in patients where the diagnosis has already been made, and for the 
detection of SCT and SCD in the wider family groupother family members.
 Ethical challenges of detecting HbS include that consent is often not requested; appropriate 
communication of the result may be difficult and unsupported by services thereafter; unexpected 
paternity being revealed; accessing incorrect information about SCT symptoms may create 
anxiety and confusion; being told partial information may lead to incorrect inferences of more 
serious conditions and revealing sickle trait status may result in a discrimination and 
stigmatisation by a range of sources and mechanisms.
 Further research is needed to explore these issues for testing centres, practitioners, patients and 
their family members in more detail and to form a basis for international guidelines.
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Fig 1 Example of chromatogram for a patient with HbAS detected through a HbA1c test, in laboratory 
files only
                                  HbA1C      HbA       HbS 
Minutes
%
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Fig 2 Extract of lab report showing wording of the HbA1c result sent to the practitioner and then passed 
onto the patient
HbA1c levl  IFCC standardized  (KST47)    34 mmol/mol 20.00-41.00mmol/mol
01 Normal
See comment below
Haemoglobin variant detected. HbA1c may be useful for monitoring diabetic control provided 
there is no reduction in red cell life. Diabetes is defined by an HbA1c > 47 mmol/mol and 
optimum glucose control at HbA1c < 59 mmol/mol.
More info go to www.pathology.[TRUSTNAME].nhs.uk and search for HbA1C
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Fig 3 Updated wording of the HbA1c result sent to the practitioners a year after the above result
Haemoglobin  n e ns ha  n vn	eable effect 
n  e v  l and 
therefore HbA1c cannot be used for diagnosis of diabetes (suggest fasting glucose). 

  e  l be useful for monitoring glycaemic control.
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Table 1. Numbers of methods, systems for HbA1c tests and their interference with variants 
Number of met ﬀﬁﬂﬁe for HbA1c tests 617
Number of A1C testing systems manufacturers Aﬃﬃ!" #$ 17
Number of systems ddﬁﬃd to measure A1C (including 
dﬀ&'
Aﬃﬃ!" ()*
17
Number of systems aﬀﬁﬂﬁd in the USA (including 
dﬀ&'
Approx. 156 17
Number of systems eﬁ+td as reported by N,-. as 
+ﬀ&u /ﬂ+t0 1dt
)# 4ﬃﬃ!" 567 8 ﬁl systems)
Number of /ﬂ+t0 studies reported by N,-.  where 
there is interference of results by Haemoglobin ﬀ&t
4
9:
-
: ;: <:
dﬁdtd
=
&
9
ﬂ'
21>? 4@#7 8 Btd1 dﬁ+ted)
Number of the 
ﬂd /ﬂ+t0
studies reported 
dﬁ+tﬀ
ng 
interference of HbS
19>?
45*7 8 Btd1 dﬁ+
ted)
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